Biosimilar erythropoiesis-stimulating agents and the risk of developing anti-drug antibodies—a systematic review-Reference-Cited by-同舟云学术

Biosimilar erythropoiesis-stimulating agents and the risk of developing anti-drug antibodies—a systematic review

Published:2016-07-21 Issue:10 Volume:72 Page:1161-1169
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Arnlind Marianne Heibert,Fryklund Linda,Vitols Sigurd,Bertilsson Göran^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00228-016-2096-z.pdf

Reference50 articles.

1. Collins A, Ellefson J (2000) Association between hematocrit level and mortality in hemodialysis patients. Case study of the anemic patient. Nephrol Nurs J 27(2):233–236

2. Standards, options and recommendations for the use of recombinant erythropoietin (epoietin alpha and beta darbepoietinalpha, EPO) in the management of anaemia in oncology for patient undergoing radiotherapy-UPDATE 2003 (2004) Cancer/Radiotherapie 8 (3):197–206

3. Doshi S, Krzyzanski W, Yue S, Elliott S, Chow A, Perez-Ruixo JJ (2013) Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents. Clin Pharmacokinet 52(12):1063–1083. doi: 10.1007/s40262-013-0098-x

4. Jelkmann W (2013) Physiology and pharmacology of erythropoietin. Transfus Med Hemother 40(5):302–309. doi: 10.1159/000356193

5. Bolasco P, Atzeni A (2011) Erythropoiesis-stimulating agents: switch from intravenous to subcutaneous administration in hemodialyzed patients. Int J Clin Pharmacol Ther 49(12):744–749

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients;Clinical Drug Investigation;2017-08-04